The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A preliminary first year report

Lupus

Volumn 21, Issue 7, 2012, Pages 766-768

  Alijotas Reig, J ^a   Ferrer Oliveras, R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antiphospholipid antibody; obstetric antiphospholipid syndrome; obstetric morbidity; registry; treatment

Indexed keywords

ACETYLSALICYLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; PREDNISONE;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE REGISTRY; FEMALE; FETUS OUTCOME; FOLLOW UP; HUMAN; LABORATORY TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MORBIDITY; OBSTETRICS; PREGNANCY OUTCOME; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; EUROPE; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84861560222     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312440058     Document Type: Conference Paper

References (14)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006 ; 4: 205-306
2. Out HJ, Kooijman CD, Bruinse HW, et al. Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynaecol Report Biol. 1991 ; 195: 211-220
3. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid- induced fetal loss by inhibiting complement activation. Nature Med. 2004 ; 10: 1222-1226
4. Alijotas-Reig J, Izquiedo M, Serra B, et al. Antiphospholipid autoantibodies, complement levels, hypergammaglobulinemia and spontaneous intrauterine haematomas in pregnant women. Am J Reprod Immunol. 2003 ; 49: 1-6
5. Carbone J, Sarmiento E, Rodriguez-Molina J, et al. Hipocomplementemia C3 y C4 en el síndrome antifosfolípido obstétrico. Rev Clin Esp. 2008 ; 208: 168-171
6. Salmon JE, Girardi G. Antiphospholipid syndrome revisited: a disorder initiated by inflammation. Lupus. 2007 ; 16 (abst suppl). 1-2
7. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid- induced fetal loss by inhibiting complement activation. Nature Med. 2004 ; 10: 1222-1226
8. Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol. 2005 ; 174: 1222-1226
9. Chu AJ. Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications. Cell Biochem Funct. 2006 ; 24: 173-192
10. Girardi G, Yarilin D, Thurman JM, et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006 ; 203: 2165-2175
11. Boffa M-C, Boinot C, de Carolis S, et al. Laboratory criteria of the obstetrical antiphospholipid syndrome (APS). Data from a multicentre prospective European women cohort. Thromb Haemost. 2009 ; 102: 25-28
12. Alijotas-Reig J, Vilardell-Tarrés M. Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?. Obstet Gynecol Surv. 2010 ; 65: 39-45
13. Branch W. Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010. Lupus. 2011 ; 20: 158-164
14. Boffa MC. Diagnostic criteria for APS. Results of a questionnaire of the European Forum on Antiphospholipid Antibodies. VII European forum on aPL, Marseille, France, 2-3 October 2009. (Oral Communication).